Is Globus Medical, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 36, a Price to Book Value of 1.98, and an EV to EBITDA of 13.54. Comparatively, its peers such as Masimo Corp. with a P/E of 179.74 and Merit Medical Systems, Inc. with a P/E of 42.46 suggest that Globus Medical's valuation is relatively high.
In terms of performance, Globus Medical has underperformed against the S&P 500, with a year-to-date return of -25.45% compared to the index's 16.30%. This trend of underperformance, alongside its elevated valuation ratios, reinforces the conclusion that the stock is overvalued in the current market environment.